pharmaphorum| News & views on pharma and biotech’s evolving future

Patients

Sponsored

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

Oncology

The growing body of evidence for GLP-1s in cancer care and p...

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

News

Pfizer targets $2.5bn more in cost savings

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.

Featured Content

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

Oncology

The growing body of evidence for GLP-1s in cancer care and p...

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

R&D

Sponsored

Patient population first: the strategy behind country decisi...

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

Newsletters and Deep Dive
digital magazine

Latest News

News

Pfizer targets $2.5bn more in cost savings

Pfizer's second-quarter results update is headlined by news of an additional $2.5 billion in cost-cutting initiatives.

News

MSD records one hit, one miss with TL1A drug tulisokibart

MSD's tulisokibart was effective in a phase 2 trial in skin disorder hidradenitis suppurativa, but has failed a study in rare lung disorder SSc-ILD.

News

NICE breast cancer criteria missing patients, claims study

NICE's criteria to decide who is referred for further breast cancer risk assessment miss up to 95% of younger women who go on to develop the disease.

News

Pathos AI signs two cancer deals with Alphamab and AZ

Pathos AI has grown its oncology pipeline by licensing a bispecific ADC from Alphamab for $125m and partnering a breast cancer drug from AstraZeneca.

Views & Analysis

Patients

Sponsored

12 Questions with Kim Innes

Kim Innes is General Manager of Teva UK. She has more than 30 years’ experience across the pharmaceutical industry.

Sales & Marketing

What does FDA's proposed DTC advertising rule mean for pharm...

Last month, the FDA quietly added a proposed rule to the 2026 Unified Agenda that – if finalised – could make prescription drug advertising untenable.

R&D